New publication: examining 12-months recurrence-free survival following photo coagulation of bladder tumor versus TUR-BT
Photocure announces the publication of the study âIn-office laser coagulation of Ta bladder tumor compared to TUR-BT: 12 months follow-up randomized clinical trialâ in the Journal of Urology last week. A first abstract of the studyâs 12-month data had been presented at the European Association of Urology (EAU) 2024 congress. Photocure has supported this program and the specific study since 2016.
Laser III is a prospective, randomized, non-inferiority trial conducted in Denmark (NCT02886026) aimed to determine whether in-office photo coagulation bladder tumor (PC-BT) is non-inferior to standard TUR-BT regarding 12-months recurrence-free survival (RFS) in patients with recurrent Ta low grade bladder tumor. Both the office-based laser procedure and TUR-BT procedure were performed under BLC-guidance, comparing the procedures with the most complete detection technology and without compromising clinical or oncological safety. From 2016 to 2022 a randomized controlled clinical trial was performed comparing PC-BT with 980 nm diode laser under local anesthesia with gold standard TUR-BT under general anesthesia, in 300 patients in a hospital setting in Denmark.
Study results show 12 months recurrence-free survival was 43.5% after PC-BT and 43.0% after TUR-BT, the difference 0.5% in favor of TUR-BT met the noninferiority criterion.
The authors conclude: âOffice-based laser photo coagulation of bladder tumor is non-inferior to TUR-BT regarding 12-months recurrence-free survival and is a safe, efficient treatment for recurrent Ta low-grade bladder tumorsâ
âThis is another quality clinical study supporting the utility of BLC for improving surgical performance, by enhancing detection of tumors and visibility of tumor margins, and its impact on clinical outcomes,â said Anders Neijber Chief Medical Officer of Photocure.
